Strategic Wealth Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$76.3K Buy
3,169
+553
+21% +$14.5K ﹤0.01% 452
2026
Q1
$73.5K Buy
2,616
+2
+0.1% +$53 0.01% 442
2025
Q4
$65.1K Sell
2,614
-954
-27% -$24.1K ﹤0.01% 472
2025
Q3
$90.9K Sell
3,568
-7,746
-68% -$191K 0.01% 450
2025
Q2
$274K Buy
+11,314
New +$264K 0.02% 285
2024
Q4
$442K Buy
17,234
+3,125
+22% +$84.8K 0.04% 219
2024
Q3
$408K Sell
14,109
-23,723
-63% -$692K 0.04% 221
2024
Q2
$1.06M Buy
+37,832
New +$1.04M 0.11% 131
2023
Q4
Sell
-10,379
Closed -$344K 293
2023
Q3
$344K Sell
10,379
-3,252
-24% -$115K 0.05% 234
2023
Q2
$500K Sell
13,631
-40,541
-75% -$1.58M 0.06% 205
2023
Q1
$2.21M Buy
54,172
+4,288
+9% +$185K 0.34% 84
2022
Q4
$2.56M Sell
49,884
-9,468
-16% -$454K 0.47% 65
2022
Q3
$2.6M Buy
59,352
+1,549
+3% +$75.3K 0.55% 54
2022
Q2
$3.03M Buy
57,803
+22,163
+62% +$1.13M 0.65% 48
2022
Q1
$1.84M Buy
35,640
+8,682
+32% +$450K 0.36% 94
2021
Q4
$1.59M Buy
26,958
+21,364
+382% +$1.06M 0.3% 107
2021
Q3
$241K Buy
5,594
+42
+0.8% +$1.86K 0.07% 215
2021
Q2
$217K Sell
5,552
-47
-0.8% -$1.83K 0.07% 213
2021
Q1
$203K Hold
5,599
0.08% 183
2020
Q4
$206K Sell
5,599
-408
-7% -$15K 0.09% 170
2020
Q3
$209K Sell
6,007
-680
-10% -$23.8K 0.11% 145
2020
Q2
$207K Sell
6,687
-6,971
-51% -$237K 0.11% 126
2020
Q1
$508K Hold
13,658
0.26% 92
2019
Q4
$508K Sell
13,658
-2,567
-16% -$91.4K 0.26% 92
2019
Q3
$9.59K Sell
16,225
-15,432
-49% -$561K 0.05% 143
2019
Q2
$1.3M Sell
31,657
-8,973
-22% -$356K 0.63% 45
2019
Q1
$1.65M Sell
40,630
-2,122
-5% -$85K 0.76% 33
2018
Q4
$1.76M Sell
42,752
-3,513
-8% -$146K 0.89% 21
2018
Q3
$1.93M Buy
46,265
+2,477
+6% +$95.4K 1.03% 18
2018
Q2
$1.51M Sell
43,788
-20,997
-32% -$718K 0.87% 22
2018
Q1
$2.18M Buy
64,785
+239
+0.4% +$8.22K 1.12% 20
2017
Q4
$2.16M Buy
+64,546
New +$2.2M 1.2% 20

Other funds holding PFE

Strategic Wealth Partners's PFE Position: Q2 2026 in Review

Strategic Wealth Partners increased its Pfizer (PFE) stake by 21% in Q2 2026, buying an estimated $14.5K and bringing the position to 3,169 shares worth $76.3K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

Strategic Wealth Partners first reported a position in PFE in Q4 2017 and has held it in 32 quarters since. The position peaked at $3.03M in Q2 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Strategic Wealth Partners held 3,169 shares of Pfizer worth $76.3K as of Q2 2026.
  • Strategic Wealth Partners bought 553 Pfizer shares in Q2 2026, an estimated $14.5K.
  • Pfizer made up ﹤0.01% of Strategic Wealth Partners's portfolio in Q2 2026, its #452 holding.
  • Strategic Wealth Partners first reported a position in Pfizer in Q4 2017 and has held it in 32 quarters since.
  • Strategic Wealth Partners's Pfizer position peaked at $3.03M in Q2 2022.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.